Dogwood Therapeutics, Inc. (DWTX NASDAQ) stock market data APIs
$4.8385
-0.01(-0.2%)
as of July 18, 2025
Try our APIs with
free plan!
Dogwood Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Prev. Close
4.8385
Open
4.8277
High
4.9118
Low
4.7924
52 wk Range
1.62-21.78
Market Cap
8 166 K
Shares Outstanding
1 332 K
EPS
-8.4504
Beta
1.938
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dogwood Therapeutics, Inc. data using free add-ons & libraries
Get Dogwood Therapeutics, Inc. Fundamental Data
Dogwood Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dogwood Therapeutics, Inc. News
New
Dogwood Therapeutics raises CFO Angela Walsh’s base salary to $321,903
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) has approved an increase in the base salary of its Chief Financial Officer, Angela Walsh. According to a statement made in a press release and filed with the S...
Dogwood Therapeutics shareholders approve equity plan amendment and elect directors
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced Tuesday that its shareholders approved an amendment to the company’s Amended and Restated 2020 Equity Incentive Plan at the annual meeting held on ...
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conferenc...
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to tre...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
